164 related articles for article (PubMed ID: 15205267)
21. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
[TBL] [Abstract][Full Text] [Related]
22. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
[TBL] [Abstract][Full Text] [Related]
23. Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.
Shiratori S; Kosugi-Kanaya M; Shigematsu A; Kobayashi H; Yamamoto S; Kobayashi N; Iwasaki H; Mori A; Kunieda Y; Yutaka T; Kurosawa M; Kakinoki Y; Endo T; Kondo T; Hashino S; Teshima T;
Leuk Lymphoma; 2015; 56(9):2592-7. PubMed ID: 25563559
[TBL] [Abstract][Full Text] [Related]
24. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
25. [The relation between clinical features of adult T-cell leukemia/lymphoma and the serum levels of soluble CD25 and CD30].
Takemoto S; Pornkuna R; Hidaka M; Kawano F
Rinsho Ketsueki; 2016 Jul; 57(7):848-53. PubMed ID: 27498727
[TBL] [Abstract][Full Text] [Related]
26. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
27. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
28. Primary cutaneous multifocal CD30+ anaplastic large cell lymphoma.
Asha LK; Thomas D; Binitha MP; Nandakumar G
Indian J Dermatol Venereol Leprol; 2006; 72(5):376-8. PubMed ID: 17050936
[TBL] [Abstract][Full Text] [Related]
29. CD30-positive anaplastic variant diffuse large B cell lymphoma: a rare case presented with cutaneous involvement.
Asano H; Imai Y; Ota S; Yamamoto G; Takahashi T; Fukayama M; Kurokawa M
Int J Hematol; 2010 Oct; 92(3):550-2. PubMed ID: 20838960
[TBL] [Abstract][Full Text] [Related]
30. Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival.
Christiansen I; Enblad G; Kälkner KM; Gidlöf C; Glimelius B; Tötterman TH
Leuk Lymphoma; 1995 Oct; 19(3-4):243-51. PubMed ID: 8535215
[TBL] [Abstract][Full Text] [Related]
31. [Clinical characteristics and prognostic factors of 40 cases of primary systemic anaplastic large cell lymphoma].
Chen YK; Yu WJ; Liu H; Wei JY; Qian WB; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):222-227. PubMed ID: 32311892
[No Abstract] [Full Text] [Related]
32. Relationship between the absolute lymphocyte count/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma.
Li C; Li W; Xu G; You M; Wu W; Kuang L
Ann Palliat Med; 2021 Oct; 10(10):10938-10945. PubMed ID: 34763456
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].
Vinogradova IuE; Lutsenko IN; Kaplanskaia IB; Vorob'ev IA; Samoĭlova RS; Gorgidze LA; Ryzhikova NA; Valiev TT; Giliazitdinova EA; Dzhulakian UL; Egorova EK; Zvonkov EE; Krasil'nikova BB; Magomedova AU; Margolin OV; Mar'in DS; Kremenetskaia AM; Kravchenko SK; Vorob'ev AI
Ter Arkh; 2008; 80(7):33-7. PubMed ID: 18763592
[TBL] [Abstract][Full Text] [Related]
34. Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia.
Chrobák L; Podzimek K; Plísková L; Kerekes Z; Zák P; Voglová J; Spacek J; Palicka V
Neoplasma; 1996; 43(5):321-5. PubMed ID: 8996552
[TBL] [Abstract][Full Text] [Related]
35. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases.
Monsalve-De Castillo F; Romero TA; Estévez J; Costa LL; Atencio R; Porto L; Callejas D
Clin Diagn Lab Immunol; 2002 Nov; 9(6):1372-5. PubMed ID: 12414777
[TBL] [Abstract][Full Text] [Related]
36. Elevated serum levels of soluble interleukin-2 receptor: a marker of disease activity in the hypereosinophilic syndrome.
Prin L; Plumas J; Gruart V; Loiseau S; Aldebert D; Ameisen JC; Vermersch A; Fenaux P; Bletry O; Capron M
Blood; 1991 Nov; 78(10):2626-32. PubMed ID: 1726707
[TBL] [Abstract][Full Text] [Related]
37. Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL).
Eisfeld H; Kircher S; Rosenwald A; Anagnostopoulos I; Werner M; Gaßler N; Wolf G; Lehmkuhl L; Teichgräber U; Gühne F; Darr A; Freesmeyer M; Weschenfelder W; Hofmann G; Dalkilic R; Kalff R; Hochhaus A; Schrenk KG
Ann Hematol; 2021 Apr; 100(4):1107-1109. PubMed ID: 32895754
[No Abstract] [Full Text] [Related]
38. The role of tumor-associated macrophages on serum soluble IL-2R levels in B-cell lymphomas.
Sakai A; Yoshida N
J Clin Exp Hematop; 2014; 54(1):49-57. PubMed ID: 24942946
[TBL] [Abstract][Full Text] [Related]
39. Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma.
Wakao D; Murohashi I; Tominaga K; Yoshida K; Kishimoto K; Yagasaki F; Itoh Y; Itoh K; Sakata T; Kawai N; Kayano H; Suzuki T; Matsuda A; Hirashima K; Bessho M
Ann Hematol; 2002 Mar; 81(3):140-6. PubMed ID: 11904739
[TBL] [Abstract][Full Text] [Related]
40. A case of primary non-Hodgkin's lymphoma of the uterine cervix treated by combination chemotherapy (THP-COP).
Nasu K; Yoshimatsu J; Urata K; Miyakawa I
J Obstet Gynaecol Res; 1998 Apr; 24(2):157-60. PubMed ID: 9631606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
